---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-102834"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:57:46.368027+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M

## Summary
- Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.
- ARCALYST net product revenue $180.9M, up 61% YoY; total revenue $180.9M.
- 2025 revenue guidance raised to $670-675M from prior $625-640M.
- KPL-387 granted Orphan Drug Designation; Phase 2/3 data H2 2026.
- Prescribers >3,825; average therapy duration ~32 months.

## SEC filing metadata
- accession: 0001104659-25-102834
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465925102834/0001104659-25-102834-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465925102834/tm2529531d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-102834
- JSON: https://secwatch.observer/filing/0001104659-25-102834.json
- Plain text: https://secwatch.observer/filing/0001104659-25-102834.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.